이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Silo Pharma 과거 수익 실적

과거 기준 확인 0/6

Silo Pharma의 수입은 연평균 -14%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 15.5%의 비율로 증가했습니다. 매출은 연평균 33%의 비율로 증가해 왔습니다.

주요 정보

-14.0%

수익 성장률

14.9%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	33.0%
자기자본 수익률	-66.6%
순이익	-4,890.8%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Oct 20

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Oct 03

수익 및 비용 분석

Silo Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:SILO 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
31 Mar 24	-4	3	1
31 Dec 23	-4	3	1
30 Sep 23	-4	3	1
30 Jun 23	-5	3	1
31 Mar 23	-4	3	1
31 Dec 22	-4	2	1
30 Sep 22	-3	2	1
30 Jun 22	4	2	1
31 Mar 22	4	2	1
31 Dec 21	3	2	1
30 Sep 21	3	2	0
30 Jun 21	-4	2	0
31 Mar 21	-5	3	0
31 Dec 20	-3	2	0
30 Sep 20	-3	2	0
30 Jun 20	-2	2	0
31 Mar 20	-1	1	0
31 Dec 19	-1	1	0
30 Sep 19	-1	1	0
30 Jun 19	-1	1	0
31 Mar 19	-1	1	0
31 Dec 18	-1	0	0
30 Sep 18	0	0	0
30 Jun 18	-1	0	0
31 Mar 18	0	0	0
31 Dec 17	0	0	0
30 Sep 17	0	0	0
30 Jun 17	0	0	0
31 Mar 17	0	0	0
31 Dec 16	-1	0	0
30 Sep 16	-1	0	0
30 Jun 16	-1	0	0
31 Mar 16	-1	0	0
31 Dec 15	0	0	0
30 Sep 15	0	0	0
30 Jun 15	0	0	0
31 Mar 15	-1	0	0
31 Dec 14	0	0	0
30 Sep 14	0	0	0
30 Jun 14	0	0	0
31 Mar 14	0	0	0
31 Dec 13	0	0	0

양질의 수익: SILO 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SILO 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SILO 은(는) 수익성이 없으며 지난 5년 동안 연간 14% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SILO 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SILO 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SILO 현재 수익성이 없기 때문에 마이너스 자본 수익률( -66.63% )을 갖습니다.

Silo Pharma 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022)

Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021)

Recent updates

Silo Pharma, Inc. announced that it has received $2.077409 million in funding

New minor risk - Shareholder dilution

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million.

New major risk - Share price stability

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023)

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment

Full year 2023 earnings: EPS misses analyst expectations

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

New minor risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA

Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022)

Silo Pharma, Inc. Announces Spc-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’S Disease

Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021)

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer's

Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares.

Silo Pharma, Inc. Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma, Inc. Initiates Study of Novel Joint Homing Peptide in Human Tissue

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$3.28 profit in 3Q 2021)

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Silo Pharma, Inc. Announces Data Supporting Therapeutic Potential of SPC -14 for Alzheimer's Disease in Pre-Clinical Study

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Investor sentiment improved over the past week

High number of new and inexperienced directors

Silo Pharma Initiates Toxicity Study of Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Silo Pharma, Inc. Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Silo Pharma, Inc. Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo Pharma, Inc. Announces Positive Results in Subcutaneous Delivery of Its Novel Liposomes to Treat Arthritic Patients

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

Silo Pharma, Inc. Enters into Exclusive Option Agreement with the University of Maryland, Baltimore for Patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into A Master License Agreement with the University of Maryland, Baltimore

Silo Pharma Inc. announced that it expects to receive $4.276 million in funding

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Inc. Announces Licensing Agreement with Aikido Pharma Inc

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma, Inc. Appoints Charles B. Nemeroff to Scientific Advisory Board

Silo Pharma Inc. Appoints Peter Hendricks to its Scientific Advisory Board

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’S Disease

Silo Pharma, Inc. Names Joshua Woolley to Newly Formed Scientific Advisory Board

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Matthew Johnson of John Hopkins University

Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides

Silo Pharma, Inc. Appoints Kevin Muñoz to Board of Directors

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기